Shares of Amag Pharmaceuticals Inc. soared after the drug developer said chief executive Brian J.G. Pereira had resigned and the company will begin a restructuring that includes cutting about 25 percent of its jobs and up to $25 million in operating expenses. Pereira will stay on as an adviser, the company said. He will be replaced on an interim basis by finance chief Frank Thomas while Amag seeks a replacement. Amag also said chief commercial officer Gary Zieziula has left the company, effective immediately. The shakeup comes two weeks after Amag said shareholders voted against issuing new stock to buy lymphoma drug maker Allos Therapeutics Inc.
For more from BostonGlobe.com, sign up or log in below
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.